Table 2.
Estimated Vaccine Efficacy Against Infection (VEin) and Vaccine Efficacy Against Progression to Symptoms (VEpr) Using Trial-reported Vaccine Efficacy Against Symptomatic Infection (VEsym) and Vaccine Efficacy Against Asymptomatic Infection (VEasym)
| Vaccine | Reported Vaccine Efficacy (%) | Calculated Vaccine Efficacy (%) | Bias Adjusted Vaccine Efficacy (%) | |||||
|---|---|---|---|---|---|---|---|---|
| VE sym | VE asym | VE in | VE in | VE pr | VE asym | VE in | VE pr | |
| Oxford-AstraZeneca ChAdOx1a [18] | 72.3 | 14.6 | 50.9 | … | 43.6 | 27.4 | 59.0 | 31.5 |
| 63.1 to 79.3 | –12.1 to 34.9 | 41.0 to 59.0 | 20.6 to 59.9 | –32.1 to 87.4 | 38.4 to 77.1 | –20.7 to 55.0 | ||
| Janssen Ad26.COV2.Sb,c [19] | 66.5 | 65.5 | … | 66.2 | 0.9 | 79.2 | 70.9 | –15.2 |
| 55.5 to 75.1 | 39.9 to 81.1 | 55.9 to 74.1 | –46.8 to 33.2 | 14.6 to 99.0 | 49.8 to 80.7 | –73.3 to 33.2 | ||
| Pfizer-BioNTech BNT162b2d [20] | 95.0 | … | … | … | … | … | … | … |
| 90.3 to 97.6 | ||||||||
| Moderna mRNA-1273d [21] | 94.1 | … | … | … | … | … | … | … |
| 89.3 to 96.8 | ||||||||
| Novavax NVX-CoV2373d [22] | 96.4 | … | … | … | … | … | … | … |
| 73.8 to 99.5 | ||||||||
| Sinovac CoronaVacd [23] | 83.5 | … | … | … | … | … | … | … |
| 65.4 to 92.1 | ||||||||
| Sinopharm BBIBP-CorVd [24] | 78.1 | … | … | … | … | … | … | … |
| 64.8 to 86.3 | ||||||||
| Gamaleya Research Institute Sputnik Vd [25] | 91.6 | … | … | … | … | … | … | … |
| 85.6 to 95.2 | ||||||||
| Bharat Biotech Covaxind [26] | 80.6 | … | … | … | … | … | … | … |
| … | ||||||||
Trials that have not yet reported an estimate are left blank. VEin and VEpr calculated using equations 3 and 4, respectively.
Abbreviations: mRNA, messenger RNA; PCR, polymerase chain reaction; VEasym, vaccine efficacy against asymptomatic infection; VEin, vaccine efficacy against infection; VEpr, vaccine efficacy against progression to symptoms; VEsym, vaccine efficacy against symptomatic infection..
VE sym measured with responsive PCR testing of symptomatic participants, VEasym measured using weekly PCR testing of asymptomatic participants, VEin estimated from all positive PCR tests collected via the alternative testing strategies for symptomatic and asymptomatic infections.
VE sym measured with responsive PCR testing of symptomatic participants, VEasym measured using serology testing of asymptomatic participants.
VE in and VEpr based on odds ratio, assuming confidence intervals are normal on the log scale.
VE sym measured with responsive PCR testing of symptomatic participants.